VIRO Stock Overview
An in vitro diagnostics company, develops and markets prognostic products for the healthcare sector. More details
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
ViroGates A/S Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | DKK 13.60 |
52 Week High | DKK 31.00 |
52 Week Low | DKK 4.98 |
Beta | 0.74 |
1 Month Change | -27.66% |
3 Month Change | 145.05% |
1 Year Change | 70.00% |
3 Year Change | -91.45% |
5 Year Change | -61.03% |
Change since IPO | -84.09% |
Recent News & Updates
Recent updates
ViroGates (CPH:VIRO) Is In A Good Position To Deliver On Growth Plans
Mar 06We're Hopeful That ViroGates (CPH:VIRO) Will Use Its Cash Wisely
Nov 21Will ViroGates (CPH:VIRO) Spend Its Cash Wisely?
Jun 14We're Not Very Worried About ViroGates' (CPH:VIRO) Cash Burn Rate
Sep 19We Think ViroGates (CPH:VIRO) Can Afford To Drive Business Growth
Apr 14We Think ViroGates (CPH:VIRO) Can Afford To Drive Business Growth
Dec 30Shareholder Returns
VIRO | DK Medical Equipment | DK Market | |
---|---|---|---|
7D | -9.9% | -4.5% | 0.6% |
1Y | 70.0% | 2.4% | 13.0% |
Return vs Industry: VIRO exceeded the Danish Medical Equipment industry which returned 2.4% over the past year.
Return vs Market: VIRO exceeded the Danish Market which returned 13% over the past year.
Price Volatility
VIRO volatility | |
---|---|
VIRO Average Weekly Movement | 26.1% |
Medical Equipment Industry Average Movement | 3.6% |
Market Average Movement | 4.3% |
10% most volatile stocks in DK Market | 11.3% |
10% least volatile stocks in DK Market | 2.6% |
Stable Share Price: VIRO's share price has been volatile over the past 3 months compared to the Danish market.
Volatility Over Time: VIRO's weekly volatility (26%) has been stable over the past year, but is still higher than 75% of Danish stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 10 | Jakob Knudsen | www.virogates.com |
ViroGates A/S, an in vitro diagnostics company, develops and markets prognostic products for the healthcare sector. It offers suPARnostic, a proprietary biomarker used in hospital emergency services to support the clinical decision on hospitalization or discharge of acute patients and to identify high-risk sepsis patients at an early stage, as well as used for the prognosis of lifestyle-related diseases, such as cardiovascular disease, type 2 diabetes, and cancer; and for the assessment of longevity and biological age in a non-hospital setting. The company’ products icludes suPARnostic TurbiLatex, a latex particle-enhanced turbidimetric immunoassay that quantitatively determines the soluble urokinase plasminogen activator receptor (suPAR) level in human K2-EDTA- or lithium heparin plasma samples; suPARnostic ELISA that provides fully quantitative results; suPARnostic Quick Triage kit, which is used in the point of care situation for early warning and patient triaging that will allow clinicians and nurses to obtain a fast patient prognosis for patient disease severity, progression and outcome; and suPARnostic POC+, a point-of-care finger prick test that detects the level of suPAR in the blood.
ViroGates A/S Fundamentals Summary
VIRO fundamental statistics | |
---|---|
Market cap | DKK 103.64m |
Earnings (TTM) | -DKK 13.23m |
Revenue (TTM) | DKK 7.25m |
14.5x
P/S Ratio-7.9x
P/E RatioIs VIRO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
VIRO income statement (TTM) | |
---|---|
Revenue | DKK 7.25m |
Cost of Revenue | DKK 1.80m |
Gross Profit | DKK 5.45m |
Other Expenses | DKK 18.69m |
Earnings | -DKK 13.23m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.71 |
Gross Margin | 75.22% |
Net Profit Margin | -182.57% |
Debt/Equity Ratio | 74.8% |
How did VIRO perform over the long term?
See historical performance and comparison